Astellas touts data from early test of stem cell-derived eye therapy
Astellas reported promising results with its stem cell-derived therapy in an age-related eye disease, though data in a handful of high-dose patients in the early-stage study raised questions.
The experimental stem cell therapy, called ASP7317 ...
Read the full article on the original site.
Read Full Article